EZH2 and T-cell and NK-cell neoplasm: While others could show first promising results by EZH2 inhibition, we could not validate a significant reduction in cell viability by GSK126 and EPZ6438 at clinically relevant concentrations in a well-characterized panel of T-cell neoplasm cell lines, each with known PRC2 mutation status and H3K27 trimethylation level (Figure 1E; Supplementary Table S4).